Indian Bank Launches SME Drug Maker Pollution Loans
This article was originally published in PharmAsia News
The State Bank of India says it will make available loans to small and medium-size pharmaceutical companies to help their facilities meet environmental standards. The targeted firms for the specially designed loans primarily are bulk drug makers. Meeting environmental standards is important to the companies that expect to qualify for U.S. FDA certification for exporting to the United States. The bank launched the loan program on a pilot basis in Andhra Pradesh. (Click here for more
You may also be interested in...
Veklury is now the first US FDA-approved treatment for COVID-19, but its limited benefits means its lifespan as a blockbuster could be short.
As negotiations between the UK and EU enter a crucial phase, the UK life sciences industry has called for more clarity and guidance on what companies can expect to face at the end of the Brexit transition period.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.